Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes
Researchers from Emory University, the University of Wisconsin-Madison and UC-Berkeley have identified a significant opportunity for psilocybin-assisted therapy in the U.S. mental healthcare landscape. As U.S. News reported, if approved by the FDA, psilocybin could be used to treat depression, with an estimated 5.1 to 5.6 million Americans potentially benefiting from the therapy.
Examining a group of patients undergoing treatment for depression, researchers determined that psilocybin could be a game-changing solution, particularly for individuals suffering from major depressive disorder (MDD) or treatment-resistant depression (TRD). These conditions, which affect millions across the country, are typically unresponsive to standard treatments, underscoring the urgent need for new solutions.
A Breakthrough Approach To Treating Depression
The study, published in Psychedelics by Genomic Press, explored the FDA’s consideration of psilocybin from Psilocybe cubensis mushrooms as a breakthrough therapy, which is a designation that allows drugs with the potential to address life-threatening conditions like severe depression, to be fast-tracked through the approval process. If …